WHO issues first comprehensive clinical guidelines for flavovirus care amid ongoing Bundibugyo outbreak

In a critical move to bolster global health defenses, the World Health Organization (WHO) has issued its first comprehensive clinical guidelines for filovirus disease care, directly responding to the ongoing and rapidly escalating Bundibugyo virus outbreak in the Democratic Republic of the Congo (DRC) and Uganda. This new framework, comprising 16 evidence-based recommendations, aims to standardize patient care and significantly improve survival rates for severe hemorrhagic fevers, a stark reminder that while the initial alert referred to 'flavovirus care', the actual threat stems from the highly lethal filovirus family, which includes Ebola. The current Bundibugyo outbreak, declared a Public Health Emergency of International Concern (PHEIC) on May 17, 2026, has already claimed 232 lives out of 896 confirmed cases in the DRC as of June 17, with an additional 19 cases and 2 deaths in Uganda, largely imported from the DRC. The crisis is exacerbated by the absence of approved vaccines or specific therapeutics for Bundibugyo virus disease, alongside pervasive community mistrust, insecurity, and displacement in affected regions like Ituri Province, which continue to severely hamper response efforts and challenge the delivery of crucial supportive care. Implementing these new guidelines will be paramount in mitigating the outbreak's devastating impact, focusing on early recognition, rapid referral, and optimized supportive care to stabilize patients and prevent further spread. The coming weeks are critical as clinical trials for promising vaccine candidates are anticipated, while the WHO continues to stress that strong community engagement, cross-border cooperation, and investment in broader health services are essential to not only contain this current emergency but also to fortify defenses against future emerging infectious diseases.